Alzheon, Inc. Expanded Access Policy

Alzheon encourages patients to speak with their treating physicians and, when possible, to participate in ongoing clinical trials with ALZ-801. Alzheon is aware that in rare cases patients with serious life-threatening diseases are unable or ineligible to participate in clinical trials and may have exhausted all available options. In these rare cases, Alzheon will consider a physician’s request for access to an Alzheon medicine outside of the clinical trial setting. All such requests must be made in accordance with local laws and regulations and must be submitted by a treating physician.

Contact Details

If you have any questions about our investigational product candidates, our ongoing clinical trials, or our expanded access policy, please contact Alzheon through the following email address: clintrialsinfo@alzheon.com.  Alzheon will acknowledge receipt of the request within 5 business days. 

Disclaimer

Alzheon may revise this expanded access policy at any time and the posting of this policy shall not serve as a guarantee of access to any specific investigational drug by any individual patient.